Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Zhuhai Trinomab Pharmaceutical Co. Ltd. operates a company patent portfolio within the Biotechnology & Pharmaceuticals technology area. There is currently 1 pending office action active for this portfolio. This action is assigned to 1 distinct examiner, which suggests a concentrated prosecution effort at this stage.
The portfolio's activity is restricted to 1 distinct art unit, aligning with the 1 distinct examiner assigned to the case. RACHEL B GILL is the busiest examiner identified in the data, currently managing 1 busiest examiner pending office action. As the total number of pending office actions is 1, RACHEL B GILL is responsible for all current examination tasks for the company.
For practitioners, this means that the prosecution strategy is focused on a single point of contact within the patent office. The presence of 1 distinct art unit indicates that the technical review is confined to one specific area of expertise. With 1 pending office action, the administrative complexity is low, and the interaction with RACHEL B GILL will be the primary factor in the portfolio's immediate progress.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GILL, RACHEL B | 1 | 65.4% | +28.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17782137 | ANTIBODY AGAINST HUMAN CYTOMEGALOVIRUS AND USE THEREOF | GILL, RACHEL B | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17782137 | ANTIBODY AGAINST HUMAN CYTOMEGALOVIRUS AND USE THEREOF | GILL, RACHEL B | — |
| Art Unit | Apps |
|---|---|
| 1600 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17782137 | ANTIBODY AGAINST HUMAN CYTOMEGALOVIRUS AND USE THEREOF | GILL, RACHEL B | 1600 | §101§112 | Final Rejection | — | Pending | Jun 02, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialZhuhai Trinomab Pharmaceutical Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Rachel B Gill has the most, with 1 of Zhuhai Trinomab Pharmaceutical Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
